Disposition of [¹⁴C]LY2606368 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumours
Latest Information Update: 10 Aug 2020
At a glance
- Drugs Prexasertib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 01 Jul 2020 Results published in the Xenobiotica
- 30 Jul 2019 Status changed from active, no longer recruiting to completed.
- 18 May 2017 Status changed from recruiting to active, no longer recruiting.